Hospital QuironSalud Córdoba, Córdoba 14004, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain.
Hospital QuironSalud Córdoba, Córdoba 14004, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba 14004, Spain; Unidad de Gestión Clínica de Neumología, Hospital Universitario Reina Sofía, Córdoba 14004, Spain.
J Steroid Biochem Mol Biol. 2025 Jan;245:106609. doi: 10.1016/j.jsbmb.2024.106609. Epub 2024 Aug 31.
Calcifediol and glucocorticoids have been repositioned for the treatment of COVID-19 and may reduce severity, the need for intensive care unit admission and death.
to identify class or profiles of patients hospitalized and treated with COVID-19 pneumonia using latent class clustering methods to assess the clinical and prognostic relevance of the resulting patients' profiles. Poor prognosis was defined as death or need for ICU admission, good prognosis, the opposite. With special interest in differential responses to calcifediol.
Reina Sofia University Hospital, Córdoba Spain.
Retrospective observational cohort study of patients admitted for COVID-19.
gov public database (NCT05819918).
(i) Age ≥ 18 and ≤ 90 years, (ii) Pneumonia characterized by the presence of infiltrates on chest X-ray or CT scan, (iii) SARS-CoV-2 infection, confirmed, and (iv) CURB Scale 65 >1.
Latent class analysis, for obtaining homogeneous clusters, without specifying a priori the belonging group, and selecting the optimal number of clusters by minimizing information criteria. Evaluating the differences between groups for each variable by means of chi-square, Fisher's exact test and Kruskal-Wallis test.
707 patients hospitalized from 10 March 2020 until 4 March 2022 were included. For the treatment variable, differences were found between class 3 (60 % treated with calcifediol only) and classes 1 (less than 1 % calcifediol only vs. 82 % treated with both), 2 (less than 1 % calcifediol only vs. 82 % treated with both) and 4 (1 % calcifediol only vs. 84 % treated with both). Class 3, (60 % with calcifediol), had a significantly better prognosis compared to patients treated with glucocorticoids alone (OR: 15.2, 95 % CI: [3.73-142], p<0.001) or no treatment (OR: 7.38, 95 % CI: [2.63-30.2], p<0.001).
our real-life study shows that calcifediol treatment significantly reduces the need for ICU admission and improved prognosis in patients hospitalized for COVID-19 pneumonia, especially in the profile of patients receiving it without glucocorticoids.
Calcifediol 和糖皮质激素已被重新定位用于治疗 COVID-19，并可能降低严重程度、入住重症监护病房的需求和死亡。
使用潜在类别聚类方法识别因 COVID-19 肺炎住院和治疗的患者的类别或特征，以评估由此产生的患者特征的临床和预后相关性。不良预后定义为死亡或需要入住重症监护病房，良好预后则相反。特别关注 calcifediol 的差异反应。
科尔多瓦雷纳索非亚大学医院，西班牙。
COVID-19 住院患者的回顾性观察队列研究。
gov 公共数据库（NCT05819918）。
（i）年龄≥18 岁且≤90 岁，（ii）肺炎特征为胸片或 CT 扫描上存在浸润，（iii）SARS-CoV-2 感染，经证实，（iv）CURB 量表>65。
潜在类别分析，用于获得同质聚类，不预先指定归属组，并通过最小化信息标准选择最佳聚类数。通过卡方检验、Fisher 确切检验和 Kruskal-Wallis 检验评估组间每个变量的差异。
纳入了 2020 年 3 月 10 日至 2022 年 3 月 4 日期间住院的 707 名患者。对于治疗变量，在第 3 类（60%仅用 calcifediol 治疗）和第 1 类（不到 1%仅用 calcifediol 治疗 vs. 82%用两者治疗）、第 2 类（不到 1%仅用 calcifediol 治疗 vs. 82%用两者治疗）和第 4 类（1%仅用 calcifediol 治疗 vs. 84%用两者治疗）之间发现了差异。第 3 类（60%用 calcifediol 治疗）与单独用糖皮质激素治疗（OR：15.2，95%CI：[3.73-142]，p<0.001）或未治疗（OR：7.38，95%CI：[2.63-30.2]，p<0.001）的患者相比，预后明显更好。
我们的真实生活研究表明，calcifediol 治疗可显著降低 COVID-19 肺炎住院患者入住重症监护病房的需求，并改善预后，特别是在不接受糖皮质激素的患者中。
